Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: abi jaoude j. Int J Radiat Oncol Biol Phys. 2024 Aug 2:S0360-3016(24)02963-8. doi: 10.1016/j.ijrobp.2024.05.033. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39352322
Improving the clinical meaning of surrogate endpoints: An empirical assessment of clinical progression in phase III oncology trials.
Sherry AD, Lin TA, McCaw ZR, Beck EJ, Kouzy R, Abi Jaoude J, Passy AH, Miller AM, Kupferman GS, Fuller CD, Thomas CR Jr, Koay EJ, Tang C, Msaouel P, Ludmir EB. Sherry AD, et al. Among authors: abi jaoude j. Int J Cancer. 2024 Dec 1;155(11):1939-1943. doi: 10.1002/ijc.35129. Epub 2024 Aug 13. Int J Cancer. 2024. PMID: 39138841
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.
Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Lin TA, et al. Among authors: abi jaoude j. Clin Cancer Res. 2024 Oct 15;30(20):4791-4799. doi: 10.1158/1078-0432.CCR-24-0566. Clin Cancer Res. 2024. PMID: 39133081
Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials.
Sherry AD, Msaouel P, Kupferman GS, Lin TA, Abi Jaoude J, Kouzy R, El-Alam MB, Patel R, Koong A, Lin C, Passy AH, Miller AM, Beck EJ, Fuller CD, Meirson T, McCaw ZR, Ludmir EB. Sherry AD, et al. Among authors: abi jaoude j. medRxiv [Preprint]. 2024 Jul 24:2024.07.23.24310891. doi: 10.1101/2024.07.23.24310891. medRxiv. 2024. PMID: 39108512 Free PMC article. Preprint.
Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials.
Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR Jr, Tang C, Msaouel P, Ludmir EB. Beck EJ, et al. Among authors: abi jaoude j. Cancer Res Commun. 2024 Aug 1;4(8):2183-2188. doi: 10.1158/2767-9764.CRC-24-0265. Cancer Res Commun. 2024. PMID: 39099199 Free PMC article.
Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.
Hsu EJ, Lin TA, Dabush DR, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Noticewala S, Yang Y, Sherry AD, Fuller CD, Thomas CR Jr, Tang C, Msaouel P, Das P, Huang B, Tian L, Sun R, Lee JJ, Meirson T, Ludmir EB. Hsu EJ, et al. Among authors: abi jaoude j. J Natl Cancer Inst. 2024 Jun 7;116(6):990-994. doi: 10.1093/jnci/djae028. J Natl Cancer Inst. 2024. PMID: 38331394
56 results